Britain has made a shocking claim amid the growing influence of the new corona variant Omicron. In fact, UK-based pharmaceutical maker GlaxoSmithKline recently claimed that preliminary laboratory tests have shown that its antibody-drug against Covid-19 is effective against the new super-mutant omicron variant. The company says that GlaxoSmithKline (GSK) developed Sotrovimab with US partner Veer (VIR) biotechnology, a monoclonal antibody-based on natural antibodies already created by humans. WHO claimed that Omicron is five times more contagious than delta variants. South African scientists, on the other hand, said it could take two to three weeks to study.
This variant of the corona has been found that initially shows mild symptoms, which prevents the patient from understanding it and then takes a dangerous form. However, most surprisingly, no complete information about Omicron has been revealed so far and UK-based pharmaceutical company GlaxoSmithKline also claimed that his antibody-drug is effective against the new super-mutant omicron variant.
Tests conducted so far claim that Sotrovimab reduces the risk of hospitalization or death by 79% in high-risk adult patients with light to moderate covid-19 in 24 hours. On the other hand, the pharmaceutical company said in a statement, "Based on the sequence of the omicron variant, we believe that Sotrovimab is likely to maintain activism and effectiveness against this variant. "
Omicron's drug Sotrovimab is a single dose antibody manufactured by GlaxoSmithKline. The drug is said to work by connecting spike proteins to the outer cover of the coronavirus. This drug prevents the virus from entering the human cell. As per the information received at present, the drug marketed as Jewoody has been recommended to be given within five days of the onset of covid-19 symptoms.